General information regarding Skin toxicty

Skin toxicity is among one of the most common AEs observed with ICPi and usually develops within the first few weeks aŒer treatment initiation. However, serious skin toxicity is rare and usually does not require dose reductions, or treatment discontinuation. The most frequent skin AEs are rash, pruritus and vitiligo. More rarely, other skin AEs have been reported with checkpoint inhibitors: alopecia areata, stomatitis, xerosis cutis and photosensitivity. Exacerbation of psoriasis has also been anecdotally reported, as well as psoriasiform or lichenoid skin reactions in patients without any history of such skin disease